Protalix BioTherapeutics, Inc. (PLX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
43/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
LosePLX / S&P 7.37% / 15.20% |
WinPLX / S&P 30.14% / 15.00% |
WinPLX / S&P 228.57% / 50.40% |
| 2026-Q13/3 |
WinPLX / S&P 20.56% / -4.33% |
WinPLX / S&P 27.80% / 11.30% |
WinPLX / S&P 350.00% / 27.70% |
| 2025-Q40/3 |
LosePLX / S&P -18.92% / 2.65% |
LosePLX / S&P -1.23% / 9.00% |
LosePLX / S&P -400.00% / 13.40% |
| 2025-Q32/3 |
WinPLX / S&P 50.00% / 8.12% |
WinPLX / S&P 35.42% / 4.61% |
LosePLX / S&P -153.85% / 13.45% |
| 2025-Q21/3 |
LosePLX / S&P -42.19% / 10.94% |
WinPLX / S&P 62.79% / 4.83% |
LosePLX / S&P -135.00% / 10.63% |
| 2025-Q11/3 |
WinPLX / S&P 36.17% / -4.27% |
LosePLX / S&P 0.18% / 4.98% |
LosePLX / S&P 0.00% / 10.57% |
| 2024-Q41/3 |
WinPLX / S&P 84.31% / 2.41% |
LosePLX / S&P -18.47% / 5.25% |
LosePLX / S&P -40.00% / 6.15% |
| 2024-Q30/3 |
LosePLX / S&P -12.82% / 5.89% |
LosePLX / S&P -28.22% / 5.89% |
LosePLX / S&P -360.00% / 6.11% |
| 2024-Q20/3 |
LosePLX / S&P -7.14% / 4.28% |
LosePLX / S&P -43.59% / 5.38% |
LosePLX / S&P -1100.00% / 5.12% |
| 2024-Q11/3 |
LosePLX / S&P -29.21% / 10.56% |
WinPLX / S&P 45.00% / 5.71% |
LosePLX / S&P -113.33% / 5.59% |
| 2023-Q41/3 |
LosePLX / S&P 7.23% / 11.69% |
WinPLX / S&P 37.48% / 6.81% |
LosePLX / S&P -116.67% / 7.78% |
| 2023-Q31/3 |
LosePLX / S&P -17.00% / -3.27% |
WinPLX / S&P 33.75% / 7.52% |
LosePLX / S&P -113.51% / -5.03% |
| 2023-Q21/3 |
LosePLX / S&P -4.76% / 8.74% |
WinPLX / S&P 48.46% / 9.50% |
LosePLX / S&P -105.13% / -8.57% |
| 2023-Q11/3 |
WinPLX / S&P 53.28% / 7.50% |
LosePLX / S&P -4.58% / 10.77% |
LosePLX / S&P -43.40% / -15.69% |
| 2022-Q42/3 |
WinPLX / S&P 31.73% / 7.56% |
WinPLX / S&P 24.22% / 11.88% |
LosePLX / S&P -51.61% / -17.99% |
| 2022-Q31/3 |
WinPLX / S&P -4.59% / -4.88% |
LosePLX / S&P -3.50% / 13.47% |
LosePLX / S&P -17.78% / -1.41% |
| 2022-Q21/3 |
WinPLX / S&P 2.83% / -16.10% |
LosePLX / S&P -5.39% / 13.71% |
LosePLX / S&P -22.00% / 11.04% |
| 2022-Q11/3 |
WinPLX / S&P 27.71% / -4.60% |
LosePLX / S&P -17.99% / 15.97% |
LosePLX / S&P PLX unavailable / 42.23% |
| 2021-Q40/3 |
LosePLX / S&P -37.59% / 11.03% |
LosePLX / S&P -39.03% / 15.00% |
LosePLX / S&P PLX unavailable / 96.40% |
| 2021-Q30/3 |
LosePLX / S&P -30.37% / 0.58% |
LosePLX / S&P -19.40% / 10.77% |
LosePLX / S&P PLX unavailable / 69.42% |
| 2021-Q20/3 |
LosePLX / S&P -57.17% / 8.55% |
LosePLX / S&P -25.67% / 6.58% |
LosePLX / S&P PLX unavailable / 51.81% |
| 2021-Q11/3 |
WinPLX / S&P 22.87% / 6.17% |
LosePLX / S&P -20.22% / -1.06% |
LosePLX / S&P PLX unavailable / 7.39% |
| 2020-Q41/3 |
LosePLX / S&P -6.20% / 12.15% |
WinPLX / S&P 15.00% / -3.72% |
LosePLX / S&P PLX unavailable / -33.42% |
| 2020-Q30/3 |
LosePLX / S&P 2.11% / 8.93% |
LosePLX / S&P -4.36% / -2.04% |
LosePLX / S&P PLX unavailable / -27.10% |
| 2020-Q22/3 |
WinPLX / S&P 61.28% / 20.54% |
WinPLX / S&P 28.30% / -0.46% |
LosePLX / S&P PLX unavailable / -27.11% |
| 2020-Q11/3 |
LosePLX / S&P -28.35% / -19.60% |
WinPLX / S&P 64.23% / 3.47% |
LosePLX / S&P PLX unavailable / -14.75% |
| 2019-Q42/3 |
WinPLX / S&P 56.19% / 9.07% |
WinPLX / S&P 59.73% / 5.36% |
LosePLX / S&P PLX unavailable / 2.99% |
| 2019-Q31/3 |
LosePLX / S&P -55.32% / 1.70% |
WinPLX / S&P 454.80% / 5.02% |
LosePLX / S&P PLX unavailable / 0.21% |
| 2019-Q22/3 |
WinPLX / S&P 6.82% / 4.30% |
WinPLX / S&P 173.88% / 6.64% |
LosePLX / S&P PLX unavailable / 8.65% |
| 2019-Q12/3 |
WinPLX / S&P 41.94% / 13.65% |
WinPLX / S&P 76.44% / 8.12% |
LosePLX / S&P PLX unavailable / 14.29% |
| 2018-Q41/3 |
LosePLX / S&P -57.53% / -13.52% |
WinPLX / S&P 62.44% / 9.05% |
LosePLX / S&P PLX unavailable / 18.23% |
| 2018-Q31/3 |
WinPLX / S&P 69.77% / 7.71% |
LosePLX / S&P -38.86% / 10.21% |
LosePLX / S&P PLX unavailable / 19.06% |
| 2018-Q21/3 |
LosePLX / S&P -20.37% / 3.43% |
WinPLX / S&P 14.95% / 9.03% |
LosePLX / S&P PLX unavailable / 14.46% |
| 2018-Q11/3 |
LosePLX / S&P -18.18% / -0.76% |
WinPLX / S&P 99.33% / 7.68% |
LosePLX / S&P PLX unavailable / 12.46% |
| 2017-Q42/3 |
WinPLX / S&P 13.79% / 6.64% |
WinPLX / S&P 129.13% / 7.03% |
LosePLX / S&P PLX unavailable / 13.82% |
| 2017-Q31/3 |
LosePLX / S&P -30.95% / 4.48% |
WinPLX / S&P 164.88% / 5.68% |
LosePLX / S&P PLX unavailable / 17.57% |
| 2017-Q21/3 |
LosePLX / S&P -38.24% / 3.09% |
WinPLX / S&P 322.78% / 4.83% |
LosePLX / S&P PLX unavailable / 17.74% |
| 2017-Q12/3 |
WinPLX / S&P 202.22% / 6.07% |
WinPLX / S&P 240.47% / 3.67% |
LosePLX / S&P PLX unavailable / 13.32% |
| 2016-Q41/3 |
LosePLX / S&P -21.05% / 3.82% |
WinPLX / S&P 110.79% / 2.09% |
LosePLX / S&P PLX unavailable / 7.05% |
| 2016-Q30/3 |
LosePLX / S&P -10.94% / 3.85% |
LosePLX / S&P -296.09% / 0.20% |
LosePLX / S&P PLX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 68.39% | 20.78% |
| Annualized return | 68.39% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 64.15% | 83.14% |
| Annualized return | 10.42% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -57.21% | 319.30% |
| Annualized return | -8.14% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |